Injectable options with established authorisation: Semaglutide 2.4 mg (Wegovy) : A once-weekly GLP-1 receptor agonist injection authorised by the MHRA for chronic weight management
Restrictions continue to rise for many GIP and GLP-1 medications: In 2025, over 82% of people with insurance plans that offer coverage for Wegovy, Zepbound, and Saxenda will encounter restrictions, like prior authorization or step therapy, that make access difficult
508,509 Bumetanide, an NKCC1 (Na + -K + -2Cl cotransporter) chloride-importer inhibitor that reduces (Cl ) i levels, enhances GABAergic inhibition, which improves the behavioural symptoms of individuals with ASD
Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, et al
Spending is anticipated to increase as manufacturers invest in outcome trials and larger production networks
Tirzepatide is administered as a subcutaneous injection once weekly